Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

ReCode Therapeutics

Pre-clinical

Pre-clinical

Therapeutic Approach

Restore CFTR Function

This program is developing suppressor tRNA delivery to treat nonsense mutations. Nonsense mutations (also known as “x” or “stop” mutations) in the CFTR gene cause the production of CFTR protein to stop prematurely. Delivery of suppressor tRNA would allow lung cells to override these premature stop signals and make full-length, functional CFTR protein.

Status

Laboratory studies to develop and test this potential therapy are underway.

Sponsor

This program is sponsored by ReCode Therapeutics and partially funded by the Cystic Fibrosis Foundation.



Contact us about ReCode Therapeutics >